Go Pro
OTCMKTS:ARNI

Arno Therapeutics (ARNI) Stock Price, News & Analysis

Arno Therapeutics logo

About Arno Therapeutics Stock (OTCMKTS:ARNI)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
8,820 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Arno Therapeutics, Inc. (OTCMKTS:ARNI) is a development‐stage biopharmaceutical company focused on the research and development of targeted therapeutics for oncology indications and rare genetic disorders. The company’s mission is to apply innovative biologic and protein engineering platforms to create therapies that address significant unmet medical needs in cancer and inherited metabolic conditions.

Arno’s pipeline centers on antibody‐based drug conjugates and recombinant fusion proteins designed to selectively target tumor cells or restore deficient enzyme activity in rare diseases. Although its programs remain in preclinical and early development stages, the company has secured intellectual property rights and in‐licensed technologies to advance multiple candidates toward Investigational New Drug (IND) filings.

To bolster its research efforts, Arno Therapeutics has entered into collaboration and licensing agreements with academic institutions and specialized biotechnology firms. These partnerships grant access to novel targeting platforms, enhance preclinical data generation and support scale‐up activities in anticipation of future clinical trials. The company aims to leverage these relationships to accelerate development timelines and de‐risk its lead programs.

Headquartered in Delray Beach, Florida, Arno Therapeutics is led by a management team with experience in biopharmaceutical development, clinical operations and regulatory affairs. The company continues to build its organizational capabilities, with the goal of advancing its pipeline and establishing a presence in U.S. and select international markets upon achieving clinical milestones.

AI Generated. May Contain Errors.

Receive ARNI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARNI Stock News Headlines

Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
ARNI Arno Therapeutics, Inc. - Seeking Alpha
See More Headlines

ARNI Stock Analysis - Frequently Asked Questions

Shares of ARNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arno Therapeutics investors own include Ampliphi Biosciences (APHB), Armata Pharmaceuticals (ARMP), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS) and

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ARNI
CIK
1195116
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (OTCMKTS:ARNI) was last updated on 8/18/2026 by MarketBeat.com Staff.
From Our Partners